Almangush Alhadi, De Keukeleire Stijn, Rottey Sylvie, Ferdinande Liesbeth, Vermassen Tijl, Leivo Ilmo, Mäkitie Antti A
Department of Pathology, University of Helsinki, 00014 Helsinki, Finland.
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.
Cancers (Basel). 2022 Mar 18;14(6):1558. doi: 10.3390/cancers14061558.
The evaluation of tumor-infiltrating lymphocytes (TILs) has received global attention as a promising prognostic cancer biomarker that can aid in clinical decision making. Proof of their significance was first shown in breast cancer, where TILs are now recommended in the classification of breast tumors. Emerging evidence indicates that the significance of TILs extends to other cancer types, including head and neck cancer. In the era of immunotherapy as a treatment choice for head and neck cancer, assessment of TILs and immune checkpoints is of high clinical relevance. The availability of the standardized method from the International Immuno-oncology Biomarker Working Group (IIBWG) is an important cornerstone toward standardized assessment. The aim of the current article is to summarize the accumulated evidence and to establish a clear premise for future research toward the implementation of TILs in the personalized management of head and neck squamous cell carcinoma patients.
肿瘤浸润淋巴细胞（TILs）作为一种有前景的癌症预后生物标志物，可辅助临床决策，其评估已受到全球关注。TILs的重要性最初在乳腺癌中得到证实，目前乳腺癌肿瘤分类中推荐使用TILs。新出现的证据表明，TILs的重要性扩展到了其他癌症类型，包括头颈癌。在免疫疗法作为头颈癌治疗选择的时代，评估TILs和免疫检查点具有高度临床相关性。国际免疫肿瘤生物标志物工作组（IIBWG）提供的标准化方法是实现标准化评估的重要基石。本文的目的是总结积累的证据，并为未来在头颈鳞状细胞癌患者个性化管理中实施TILs的研究建立明确的前提。
